Over the last several years, the pharmaceutical industry has grown accustomed to volatility. What many expected to be a return to stability in 2025 instead became another chapter of unpredictability—characterized by delayed investment decisions, shifting global dynamics, and a cautious financial environment. While funding has not disappeared, it has largely remained on the sidelines as companies and investors waited for clearer signals before committing to new development programs.

As the industry looks ahead to 2026, however, there is a growing sense that momentum is beginning to rebuild. The question facing many sponsors is not if investment will return, but when—and whether they are positioned to move quickly when it does.

Uncertainty Slows Investment—But It Doesn’t Eliminate Demand

Across the industry, conversations with investors and development partners point to the same conclusion: capital has been withheld, not withdrawn. Development programs, clinical plans, and manufacturing strategies are largely intact, waiting for the confidence needed to move forward.

For API development and manufacturing partners, this has resulted in an unusual backlog of proposals—programs that have not been lost, but paused. As confidence returns and investment decisions accelerate, the challenge for sponsors will be securing reliable capacity in a market that may tighten quickly.

The Advantage of Being Ready Before the Market Turns

While some organizations are only now beginning to explore onshoring or expanded U.S. manufacturing, Olon USA has spent years laying the groundwork. That preparation is now becoming a meaningful differentiator.

Olon USA’s U.S. campus spans more than 25 acres, offering both physical space and regulatory readiness for expansion. Environmental assessments, air permits, and feasibility studies are already in place—significantly reducing timelines for sponsors seeking to scale manufacturing domestically. This foundation allows programs to move forward without the delays often associated with greenfield or early-stage facilities.

In parallel, Olon USA continues to invest in infrastructure, including the addition of larger-scale reactors capable of supporting commercial manufacturing. With multiple commercial approvals already secured and additional filings anticipated in late 2026 and early 2027, the site is steadily evolving from a development-focused operation into a balanced mix of R&D, clinical, and commercial production.

Capacity Planning in a Reawakening Market

As companies pivot toward commercial manufacturing to stabilize revenue, industry capacity is likely to become constrained—particularly if investment accelerates mid-year. Sponsors who wait may find themselves competing for limited availability, pushing development timelines further into the future.

By contrast, organizations that engage early—finalizing plans in Q1 and initiating manufacturing activities in Q2—are better positioned to stay ahead of the curve. Olon USA’s ability to support programs from early development through commercial production within the same U.S. facility offers continuity, speed, and long-term supply security.

Stability Regardless of Market Timing

Importantly, Olon USA’s strategy is not dependent on short-term market swings. By intentionally expanding its commercial manufacturing capabilities while maintaining strong development and clinical support, the organization has created a resilient operating model.

Whether investment rebounds quickly or continues to recover gradually, Olon USA remains positioned for stability. This balanced approach ensures that sponsors are not partnering with a startup chasing opportunity, but with an established manufacturer prepared to support programs across the full lifecycle.

Preparing Now for What Comes Next

As sponsors and investors begin to re-engage, preparation will be critical. Finalizing development plans, generating early-stage data, and building strong due-diligence packages can significantly accelerate funding conversations once momentum returns.

Olon USA continues to work with clients in early Q1 to support these efforts—helping sponsors enter the year with clarity, confidence, and executable plans rather than scrambling for capacity later.

Looking Ahead

While “normal” may no longer exist in a post-COVID industry, one thing remains clear: the next wave of development is forming. Sponsors who act now—partnering with organizations that have already invested in infrastructure, expertise, and long-term capacity—will be best positioned to lead it.

Olon USA enters 2026 prepared, experienced, and ready to support the next generation of medicines—whatever shape the market ultimately takes.